Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy

被引:0
|
作者
Tsavaris, N [1 ]
Mylonakis, N [1 ]
Bacoyiannis, C [1 ]
Kosmas, C [1 ]
Kalergis, G [1 ]
Iakovidis, V [1 ]
Tzaninis, D [1 ]
Kosmidis, P [1 ]
机构
[1] Metaxa Canc Hosp, Dept Med Oncol 2, Piraeus 18537, Greece
关键词
antiemetic activity; metoclopramide; cisplatin;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Some clinical parameters play a role in developing effective antiemetic therapy. In the present study, 310 patients entered and 301 were evaluable. They received cisplatin based combination chemotherapy (100 mg/m(2)), with antiemetic therapy based in metoclopramide, at a standard dose and schedule (2 mg/kg in 5 doses). Patient characteristics such as age, sex, performance status (Karnofsky), site of primary tumor, weight loss >15%, previous chemotherapy, previous radiotherapy, history of vomiting during pregnancy, additional drugs (dexamethasone, alprazolam), in the antiemetic regimen were included in the evaluation. We also studied the manifestation of anxiety and depression and the presence of psychosocial problems related to therapy, evaluated them with specific psychological indexes modified for our study. We evaluated incidence of vomiting, retches, and nausea, with several scales. We distinguished three groups of factors influencing nausea and vomiting. Factors that predicted for increased nausea and vomiting was gender (women), stress and age (younger patients experienced more prolonged duration and higher grades of nausea). The addition of alprazolam (a sedative drug) and dexamethasone, was associated with decreased incidence of nausea and vomiting. The weight loss (increased nausea and decreased vomiting control according to Gralla's scale). Previous chemotherapy decreased the number of patients without nausea and vomiting control according to Gralla's scale. Patients with previous radiotherapy presented an increased grade of nausea. Patients with head and neck cancer presented less nausea with shorter duration, less frequent episodes of vomiting. Patients with ovarian cancer presented increased mean number of retches. In conclusion, despite difficulties in assessing nausea and vomiting among clinical trials, several factors, especially stress, gender, weight loss, additional drugs (corticosteroids and sedatives) may play an important role in modulating the antiemetic response.
引用
收藏
页码:1147 / 1155
页数:9
相关论文
共 50 条
  • [31] HIGH-DOSE METOCLOPRAMIDE AND DEXAMETHASONE AS AN ANTIEMETIC IN CHEMOTHERAPY OF BREAST-CANCER
    GEZ, E
    GOODMAN, S
    ISACSON, R
    GERRA, C
    SULKES, A
    ONCOLOGY, 1986, 43 (03) : 173 - 175
  • [32] BETAMETHASONE-DIXYRAZINE VERSUS METOCLOPRAMIDE AS ANTIEMETIC TREATMENT IN CANCER-CHEMOTHERAPY
    SORBE, B
    HALLEN, C
    ACTA ONCOLOGICA, 1988, 27 (04) : 357 - 360
  • [33] The evolving landscape of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: inspiration from cisplatin-based antiemetic and non-antiemetic trials
    Sun, Ya
    Wang, Yalan
    Chen, Gang
    Zhang, Yaxiong
    Zhang, Li
    Chen, Xi
    SUPPORTIVE CARE IN CANCER, 2024, 32 (12)
  • [34] PHASE-III DOUBLE-BLIND COMPARISON OF INTRAVENOUS ONDANSETRON AND METOCLOPRAMIDE AS ANTIEMETIC THERAPY FOR PATIENTS RECEIVING MULTIPLE-DAY CISPLATIN-BASED CHEMOTHERAPY
    SLEDGE, GW
    EINHORN, L
    NAGY, C
    HOUSE, K
    CANCER, 1992, 70 (10) : 2524 - 2528
  • [35] A new standard antiemetic regimen for patients receiving cisplatin chemotherapy
    Nature Clinical Practice Oncology, 2006, 3 (9): : 467 - 468
  • [36] The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: A randomized crossover trial
    Chua, DTT
    Sham, JST
    Au, GKH
    Choy, D
    Kwong, DLW
    Yau, CC
    Cheng, ACK
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (05) : 403 - 408
  • [37] DIFFERENCE IN THE INHIBITION OF PLASMA CHOLINESTERASE ACTIVITY BY ANTIEMETIC METOCLOPRAMIDE IN HUMANS AND MICE
    RAO, SS
    KAVEESHWAR, U
    MISHRA, PK
    PHARMAZIE, 1992, 47 (01): : 66 - 67
  • [38] COMPARISON OF THE ANTIEMETIC EFFICACY OF DOMPERIDONE, METOCLOPRAMIDE AND DEXAMETHASONE IN OUT-PATIENTS RECEIVING CHEMOTHERAPY
    CUNNINGHAM, D
    EVANS, C
    POPLE, A
    DEARLING, J
    CHAPPELL, D
    COOMBES, RC
    BRITISH JOURNAL OF CANCER, 1987, 56 (02) : 226 - 226
  • [39] RANDOMIZED COMPARISON OF THE ANTIEMETIC EFFECTS OF METOCLOPRAMIDE AND ELECTRO-ACUPUNCTURE IN CANCER-CHEMOTHERAPY
    DUNDEE, JW
    GHALY, RG
    FITZPATRICK, KTJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 25 (05) : P678 - P679
  • [40] Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy
    Tsavaris, NB
    Koufos, C
    Katsikas, M
    Dimitrakopoulos, A
    Athanasiou, E
    Linardaki, G
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1999, 18 (03) : 218 - 222